Anti-PRP IgG antibody response can be produced in the human body, and immune memory can be formed. The induced specific antibodies have bactericidal and opsonization functions.

This product is used to prevent invasive infections caused by Haemophilus influenzae type b. Its main capsular polysaccharide PRP (polyribosylribitol phosphate) can produce anti-PRP IgG antibody response in the human body and form immune memory. Activity studies have shown that the specific antibodies induced by the Haemophilus influenzae type b conjugate vaccine in newborns and children have bactericidal and opsonization functions. Immunogenicity studies have shown that after the second targeted vaccination of infants aged 2 months and above, an average of 90% of anti-PRP antibody titers are 0.15mg/ml. After the third injection, almost all of them are positive, and about 90% of them exceed 1mg/ml. After 3-4 month old infants are vaccinated with 3 injections of this product, a booster injection is given 8-12 months later. Regardless of whether it is a conjugated polysaccharide vaccine or a non-conjugated polysaccharide vaccine, the titer of PRP antibodies is significantly increased, 10 times higher than the average. This confirms that the initial vaccination of this product established immune memory, and suggests that when the vaccinated children are naturally infected, the surface capsule of the pathogenic bacteria should stimulate a considerable recall response. After one injection of this product was given to children aged 12-24 months, more than 80% of them converted to positive (anti-PRP antibody 1mg/ml).

This product is used to prevent invasive infections caused by Haemophilus influenzae type b. Its main capsular polysaccharide PRP (polyribosylribitol phosphate) can produce anti-PRP IgG antibody response in the human body and form immune memory. Activity studies have shown that the specific antibodies induced by the Haemophilus influenzae type b conjugate vaccine in newborns and children have bactericidal and opsonization functions. Immunogenicity studies have shown that after the second targeted vaccination of infants aged 2 months and above, an average of 90% of anti-PRP antibody titers are 0.15mg/ml. After the third injection, almost all of them are positive, and about 90% of them exceed 1mg/ml. After 3-4 month old infants are vaccinated with 3 injections of this product, a booster injection is given 8-12 months later. Regardless of whether it is a conjugated polysaccharide vaccine or a non-conjugated polysaccharide vaccine, the titer of PRP antibodies is significantly increased, 10 times higher than the average. This confirms that the initial vaccination of this product established immune memory, and suggests that when the vaccinated children are naturally infected, the surface capsule of the pathogenic bacteria should stimulate a considerable recall response. After one injection of this product was given to children aged 12-24 months, more than 80% of them converted to positive (anti-PRP antibody 1mg/ml).

This product is used to prevent invasive infections caused by Haemophilus influenzae type b. Its main capsular polysaccharide PRP (polyribosylribitol phosphate) can produce anti-PRP IgG antibody response in the human body and form immune memory. Activity studies have shown that the specific antibodies induced by the Haemophilus influenzae type b conjugate vaccine in newborns and children have bactericidal and opsonization functions. Immunogenicity studies have shown that after the second targeted vaccination of infants aged 2 months and above, an average of 90% of anti-PRP antibody titers are 0.15mg/ml. After the third injection, almost all of them are positive, and about 90% of them exceed 1mg/ml. After 3-4 month old infants are vaccinated with 3 injections of this product, a booster injection is given 8-12 months later. Regardless of whether it is a conjugated polysaccharide vaccine or a non-conjugated polysaccharide vaccine, the titer of PRP antibodies is significantly increased, 10 times higher than the average. This confirms that the initial vaccination of this product established immune memory, and suggests that when the vaccinated children are naturally infected, the surface capsule of the pathogenic bacteria should stimulate a considerable recall response. After one injection of this product was given to children aged 12-24 months, more than 80% of them converted to positive (anti-PRP antibody 1mg/ml).

For the prevention of epidemic cerebrospinal meningitis caused by groups A, C, Y, and W135 meningococci

The specific pharmacological action description cannot be clearly extracted from the information

Induce the body to produce an immune response to prevent epidemic cerebrospinal meningitis caused by the corresponding group of meningococci

Induce the body to produce an immune response to prevent epidemic cerebrospinal meningitis caused by the corresponding group of meningococci